Humacyte, Inc. (NASDAQ: HUMA) reported fourth‑quarter and full‑year 2025 results that fell short of consensus revenue expectations but met earnings expectations. Q4 revenue was $0.5 million versus a consensus of roughly $1.35 million, while full‑year revenue reached $2.0 million, above the $1.34 million consensus estimate. Earnings per share were $‑0.13, exactly in line with the $‑0.13 consensus, and the company confirmed that its guidance for the next fiscal year remains unchanged.
The revenue miss reflects the company’s first year of commercial operations following FDA approval of its Symvess graft in December 2024. Q4 2025 revenue rose from $0 in Q4 2024, but the company still recorded a net loss of $24.8 million, compared with a $20.9 million loss in Q4 2024. Full‑year 2025 revenue of $2.0 million represents a jump from $0 in 2024, yet the company’s cost of goods sold was $9.1 million, largely driven by an $8.9 million inventory reserve that reduced inventory to net realizable value due to the lack of a sales history. These high burn costs keep the loss in line with analyst expectations.
EPS met expectations because the company maintained disciplined cost control despite the inventory reserve and high COGS. The $‑0.13 EPS, matching consensus, indicates that the company’s operating expenses were largely in line with forecasts, even as it continues to invest heavily in scaling production and commercializing Symvess.
CEO Dr. Laura Niklason highlighted several key developments. Symvess was launched in the U.S. market in February 2025 and the company secured a $1.475 million purchase commitment in Saudi Arabia announced March 19 2026. U.S. Department of Defense funding for procurement of the bioengineered vessels was announced February 9 2026. The company also previewed top‑line interim results from the V012 Phase 3 hemodialysis access study, expected in Q2 2026, which could lead to a supplemental BLA filing later that year.
Market reaction to the earnings was negative, with the stock falling between 4.9% and 5.5% in pre‑market trading. The primary driver was the Q4 revenue miss, which investors interpreted as a sign that early‑stage commercial traction is slower than anticipated. The unchanged guidance, however, was viewed as a signal of management confidence in the long‑term trajectory of Symvess and the broader dialysis and coronary pipelines.
Looking ahead, Humacyte’s guidance remains unchanged, underscoring management’s confidence in the company’s growth path. The company’s tailwinds include FDA approval, DoD funding, a significant international purchase commitment, and the upcoming V012 study results. Headwinds persist in the form of high burn, a large inventory reserve, and the challenges of scaling a first‑in‑class product. Together, these factors paint a picture of a company in the early stages of commercialization that is managing costs while pursuing aggressive growth opportunities.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.